99,778 Shares in Amedisys, Inc. (NASDAQ:AMED) Acquired by First Trust Advisors LP

First Trust Advisors LP purchased a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 99,778 shares of the health services provider's stock, valued at approximately $9,059,000. First Trust Advisors LP owned about 0.30% of Amedisys at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Gamco Investors INC. ET AL boosted its position in shares of Amedisys by 0.5% in the fourth quarter. Gamco Investors INC. ET AL now owns 30,334 shares of the health services provider's stock valued at $2,754,000 after acquiring an additional 159 shares during the period. XTX Topco Ltd acquired a new stake in Amedisys in the 4th quarter worth about $1,970,000. Barclays PLC boosted its holdings in Amedisys by 333.4% in the 4th quarter. Barclays PLC now owns 67,310 shares of the health services provider's stock valued at $6,112,000 after purchasing an additional 51,781 shares during the period. Sagespring Wealth Partners LLC acquired a new position in shares of Amedisys during the 4th quarter worth approximately $262,000. Finally, Water Island Capital LLC increased its holdings in shares of Amedisys by 0.3% during the fourth quarter. Water Island Capital LLC now owns 603,565 shares of the health services provider's stock worth $54,798,000 after purchasing an additional 1,950 shares during the period. 94.36% of the stock is currently owned by institutional investors.

Amedisys Price Performance

NASDAQ AMED traded up $0.80 on Friday, hitting $96.00. 1,114,163 shares of the company's stock were exchanged, compared to its average volume of 413,398. The stock has a 50-day moving average of $92.58 and a 200-day moving average of $91.70. The stock has a market cap of $3.15 billion, a price-to-earnings ratio of 38.10, a P/E/G ratio of 1.78 and a beta of 0.96. Amedisys, Inc. has a 52 week low of $82.15 and a 52 week high of $98.95. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 EPS for the quarter, topping analysts' consensus estimates of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Amedisys's revenue was up 4.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.03 EPS. Analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on AMED shares. Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Amedisys in a research report on Wednesday, April 16th. Stephens reissued an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a report on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $100.75.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.